-fiff˝˙ˆ- REVOLUTIONARY fi- -fifi CANCER RELAPSE …...-fiff˝˙ˆ- fi- -fifi fifi ˇ˘˝ ˘ ˘...
Transcript of -fiff˝˙ˆ- REVOLUTIONARY fi- -fifi CANCER RELAPSE …...-fiff˝˙ˆ- fi- -fifi fifi ˇ˘˝ ˘ ˘...
REVOLUTIONARY CANCER RELAPSE DETECTION IN A SIMPLE BLOOD TEST NON-INVASIVE | PAIN FREEINNOVATIVE
Aspect liquid biopsy supports targeted treatment decisions by detecting cancer recurrence earlier using cfDNA biomarkers through an innovative yet simple blood test.
VISIT OUR WEBSITE TO LEARN MORE CLINICALLABS.COM.AU/ASPECT
Visit our website to learn more clinicallabs.com.au/aspect
REVOLUTIONARY CANCER RELAPSE DETECTION IN A SIMPLE BLOOD TESTNON-INVASIVE | PAIN FREE | INNOVATIVE
Aspect Liquid Biopsy supports targeted treatment decisions bydetecting cancer recurrence earlier using cfDNA biomarkersthrough an innovative yet simple blood test.
GP
Australian Clinical Labs is the first national private laboratory in Australia to introduce the innovation of liquid biopsy.
Aspect Liquid Biopsy uses the latest technology to
analyse a bio-fluid sample to assess the genetic makeup
of a tumour. The process for patients is the same as a
standard blood test which is non-invasive and pain free,
saving time and money without the need to undergo an
invasive procedure or hospital admission.
Unlike traditional biopsies which can be invasive, painful
and require recovery time, Aspect Liquid Biopsy is a non-
invasive, simple blood test which can be used to monitor
cances including melanoma, lung and colorectal using
cell-free DNA biomarkers in blood.
Earlier detection can support better treatment decisions.
Aspect Liquid Biopsy can improve patient outcomes and
increase survival rates by detecting cancer recurrence
earlier than the current conventional methods, such as
imaging, invasive techniques and blood tumour markers.
Why is liquid biopsy so important?
Aspect Liquid Biopsy has been made possible by
advances in sequencing the human genome. Using
the tumour-derived circulating DNA, Aspect Liquid
Biopsy allows the detection of the tumour somatic
mutations that commonly occur in cancers, enabling the
identification of the actionable gene targets (e.g. EGFR in
lung cancer, KRAS in colorectal and BRAF in melanoma),
thus correlating with clinical parameters and facilitating
monitoring and treatment selection.
Cancer genetic profile in a simple blood test
Supporting the most effective treatment decisions.
After a traditional biopsy, a tissue
sample taken may not contain
tumour tissue, or may not qualify
for DNA mutation testing due
to degraded DNA quality, or an
insufficient quantity to run the assay.
Over time, resistant clones
containing other variants may grow
out of the tumour - variants that
were not detected from the initial
solid tissue biopsy. This makes the
genetic makeup of the original
tumour historical.
Aspect Liquid Biopsy enables
the discovery of those new DNA
markers in the blood in real time,
supporting the most effective
treatment decisions.
How to order
When should it be ordered?
What is the cost?
How is it collected?
Health Practitioners can order Aspect Liquid Biopsy for
cancer patients using the Aspect request form. Some
required information is listed on the form, including
the type of cancer, whether it is a new diagnosis and
if the patient is on anti-tumour therapy (if known).
Health Practitioners can download the Aspect
Liquid Biopsy form on the Clinical Labs website at
clinicallabs.com.au/aspect
Health Practitioners can order Aspect Liquid Biopsy
for cancer patients any time during management
stages.
Out of pocket fee of $550.
(No Medicare rebate available)
This test requires two
10ml blood samples which
can be taken at any of our
collection centres.
When will results be available?
Results will be available
after 5-7 business days
from the sample receipt
date.
Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the
National Clinical Director of Molecular Genetic Pathology at Australian Clinical
Labs. Associate Professor Saad’s PhD research allowed her to gain unique
experience in a wide range of biochemical, molecular genetics and cancer
targeting. She has published several articles both locally and internationally.
At Clinical Labs, Assoc. Prof Mirette Saad leads the Molecular Genetic testing
for hereditary disorders, personalised drug therapy, somatic mutation and
gene expression profile testing in cancer.
Assoc. Prof. Mirette SaadMBBS (HONS), MD (HONS), MAACB, FRCPA, PHD
National Clinical Director of Molecular Genetic Pathology,
Australian Clinical Labs
“A Personalised Medicine approach in cancer care is not new. What is new, however, is our ability to predict cancer recurrence based on the differences between individuals at molecular levels. This means that we can sub-group, or sub-stratify patients in a more meaningful way, with the potential to modify therapeutic regimes to match their individual genetic profile.”
P: (03) 9538 6777
www.clinicallabs.com.au
ACLM
AR-R
EQ-N
AT-0
027.
7 4
/18
ACL
ZPAD
0060
1300 453 688VIC NSW SA NT
Western Australia
1300 367 674
Requesting Doctor:
Provider Number:
Address:
Suburb:
Given Name:
Date of Birth:
Address:
Suburb:
Phone:
Hospital Name:
Signature:
Gender: .
Gene Target Tick if Required
c MALE
c Non-small cell lung cancer
c Melanoma
c FEMALE
Patient Details
Test Required
Clinical Details
Is this a new diagnosis?
Has the patient been treated with systemic anti-tumour therapy?
Previous somatic mutationdetected (if known):
Patient Stage:
Tumour Type:
Clinical Information
Date:
Post Code:State:
Medicare Number:
Surname:
c Colorectal Panel - RAS, PIK3CA, BRAF (EGFR)
c Lung Panel - KRAS, PIK3CA, BRAF, EGFR (incl. T790M)
c Melanoma Panel - NRAS, BRAF
c Colorectal carcinoma
x
For a current list of centres, please visit our website www.clinicallabs.com.au
or contact us on 1300 453 688 (VIC, NSW, SA & NT) or on 1300 367 674 (WA
only). All of our collection centres across Victoria, New South Wales and Western
Australia collect for Aspect Liquid Biopsy. Collection centres in South Australia
and Northern Territory require appointments for the Aspect Liquid Biopsy Test.
Please contact us to find your nearest collection centre and book an appointment.
1 Please complete patient details, clinical information,
patient informed consent and clinician details in FULL
2 Collect Two Tubes of Whole Blood into Roche, Cell
Free DNA tubes (White cap: Used also for Harmony)
– Mix well & gently
3 Transport at Ambient Room temperature – Do not centrifuge
In some infrequent cases, it will not be possible to generate an Aspect Liquid Biopsy result. Should this occur you may choose to provide a new blood sample for testing. No additional fees will be incurred for the second test. In the event that you decide not to submit an additional sample for testing, Australian Clinical Labs will refund the full test fee paid. Results will be made available to you through your nominated doctor.
Instructions For Collectors Collection Centres
c Yes
c Yes
c No
c No
Referring Clinician Details Copy Doctor Details
Patient Informed Consent
Referring Clinician Signature:
Name:
Address:
Suburb:
Phone:
Copy Hospital:
Fax:
State: Post Code:
x Date:
Patient Signature:x Date:
My signature on this form indicates that I understand the informed consent and give permission to Australian Clinical Labs to perform the laboratory Aspect Liquid Biopsy tests selected. I have had the opportunity to ask questions and discuss the capabilities and limitations with my healthcare provider. I have been informed that there is no Medicare Rebate for this test and agree to pay the out-of-pocket fee.
Fax:
Post Code:
Phone:
State:
This test has a fee of $550 (per panel).
Please tick one: c Invoice c Pay over the phone (receipt_______________)
x2
Visit our website to learn more
clinicallabs.com.au/aspect
REVOLUTIONARY CANCER RELAPSE DETECTION IN A SIMPLE BLOOD TEST NON-INVASIVE | PAIN FREEINNOVATIVE
Aspect liquid biopsy supports targeted treatment decisions by detecting cancer recurrence earlier using cfDNA biomarkers through an innovative yet simple blood test.
VISIT OUR WEBSITE TO LEARN MORE CLINICALLABS.COM.AU/ASPECT
ACLM
AR-B
F-NA
T-01
76.8
4/1
8AC
LZBC
H001
7
The word aspect is defined as a unique view or perspective.
Through Aspect Liquid Biopsy, we can offer an unprecedented view
of the genetic signatures of cancer relapse, allowing clinicians to
catch it early and make the most effective treatment decisions.
Advanced Technology
Highly Sensitive and Specific Assay
Expertise in Diagnostic Oncology
Accurate and Comprehensive Reports
High-Quality, Personalised Cancer Care
Rapid Turnaround Time
VISIT OUR WEBSITE TO LEARN MORE
CLINICALLABS.COM.AU/ASPECT
1. Fleischhacker M et al., (2007) Biochem Biophys Acta 1775; 181-232.2. John T et al., (2017) Asia-Pacific J of Clin Oncol 13; 296-303.
3. Thierry AR et al., (2014) Nat Med 20; 430-35.4. Newman AM et al., (2014) Nat Med 20; 548-54.
5. Thress et al., (2015) Lung Cancer 90; 509-15.6. Wu YL et al., (2017) Br J cancer 116; 175-85.
7. Tie et al., (2016) Sci Transl Med 8; 346ra92.8. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Non-small cell lung cancer (7 April 2017)